Recombinant human TGF beta 1 protein (Active) (ab50036)
Key features and details
- Expression system: HEK 293 cells
- Purity: > 98% SDS-PAGE
- Endotoxin level: < 1.000 Eu/µg
- Active: Yes
- Suitable for: HPLC, SDS-PAGE, Functional Studies, WB
Product nameRecombinant human TGF beta 1 protein (Active)
See all TGF beta 1 proteins and peptides
The ED50, as determined by TGF-beta1's ability to inhibit the mouse IL-4-dependent proliferation of mouse HT-2 cells, is ≤ 0.05 ng/ml), corresponding to a specific activity of ≥ 2 x 107 units/mg.
Purity> 98 % SDS-PAGE.
> 98% by HPLC analyses. Endotoxin Level: < 0.1 ng/µg of protein (< 1 EU/µg).
Endotoxin level< 1.000 Eu/µg
Expression systemHEK 293 cells
Protein lengthProtein fragment
SequenceALDTNYCFSS TEKNCCVRQL YIDFRKDLGW KWIHEPKGYH ANFCLGPCPY IWSLDTQYSK VLALYNQHNP GASAAPCCVP QALEPLPIVY YVGRKPKVEQ LSNMIVRSCK CS
Predicted molecular weight25 kDa
Amino acids279 to 390
Additional sequence informationTGF-beta1 is a 25.0 kDa protein with each subunit containing 112 aa, linked by a single disulfide bond. It is the mature protein after cleavage of the signal peptide and latency-associated peptide.
Our Abpromise guarantee covers the use of ab50036 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
TGF-beta is secreted predominantly as latent complexes which are stored at the cell surface and in the extracellular matrix.
The release of biologically active TGF-β isoform from a latent complex involves proteolytic processing of the complex and /or induction of conformational changes by proteins such as thrombospondin-1.
TGF-β1 is the most abundant isoform secreted by almost every cell type.
Concentration information loading...
Preparation and Storage
Stability and Storage
Shipped at 4°C. Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle.
This product is an active protein and may elicit a biological response in vivo, handle with caution.
ReconstitutionCentrifuge the vial prior to opening. Reconstitute in 10mM Citric Acid, pH3.0 to a concentration of 50 µg/ml (e.g. 5 µg/100µl). This solution can then be stored at room temperature or at 4oC for 1 month. It is recommended that further dilutions be made in PBS containing 2 mg/ml albumin and stored at -20oC for future use.
- Cartilage-inducing factor
- Differentiation inhibiting factor
FunctionMultifunctional protein that controls proliferation, differentiation and other functions in many cell types. Many cells synthesize TGFB1 and have specific receptors for it. It positively and negatively regulates many other growth factors. It plays an important role in bone remodeling as it is a potent stimulator of osteoblastic bone formation, causing chemotaxis, proliferation and differentiation in committed osteoblasts.
Tissue specificityHighly expressed in bone. Abundantly expressed in articular cartilage and chondrocytes and is increased in osteoarthritis (OA). Co-localizes with ASPN in chondrocytes within OA lesions of articular cartilage.
Involvement in diseaseDefects in TGFB1 are the cause of Camurati-Engelmann disease (CE) [MIM:131300]; also known as progressive diaphyseal dysplasia 1 (DPD1). CE is an autosomal dominant disorder characterized by hyperostosis and sclerosis of the diaphyses of long bones. The disease typically presents in early childhood with pain, muscular weakness and waddling gait, and in some cases other features such as exophthalmos, facial paralysis, hearing difficulties and loss of vision.
Sequence similaritiesBelongs to the TGF-beta family.
The precursor is cleaved into mature TGF-beta-1 and LAP, which remains non-covalently linked to mature TGF-beta-1 rendering it inactive.
Cellular localizationSecreted > extracellular space > extracellular matrix.
- Information by UniProt
All lanes : Anti-CTGF antibody [EPR20728] (ab209780) at 1/1000 dilution
Lane 1 : NIH/3T3 (mouse embryonic fibroblast) starved for 18 hours, whole cell lysate
Lane 2 : NIH/3T3 starved for 18 hours, then treated with 10 ng/ml transforming growth factor-ß (TGF-ß1, ab50036) and 50 µg/ml Heparin sodium salt for 24 hours, whole cell lysate
Lane 3 : HepG2 (human hepatocellular carcinoma epithelial cell), whole cell lysate
Lysates/proteins at 20 µg per lane.
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/100000 dilution
Blocking/Dilution buffer and concentration: 5% NFDM/TBST.
The level of CTGF expression can be induced by TGF beta treatment (PMID: 17786299).
CTGF is constitutively expressed in HepG2 cells (PMID:15886528).
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
Datasheets and documents
ab50036 has been referenced in 44 publications.
- Cai H et al. Overexpressed integrin alpha 2 inhibits the activation of the transforming growth factor ß pathway in pancreatic cancer via the TFCP2-SMAD2 axis. J Exp Clin Cancer Res 41:73 (2022). PubMed: 35193647
- Zhong R et al. Regulation of Ion Channel Function in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes by Cancer Cell Secretion Through DNA Methylation. Front Cardiovasc Med 9:839104 (2022). PubMed: 35265687
- Sharma A et al. Proteomic analysis of TGFβ-induced A549 secretome identifies putative regulators of epithelial-mesenchymal transition. Biotechnol Appl Biochem 69:442-450 (2022). PubMed: 33559923
- Yin J et al. Emodin suppresses hepatocellular carcinoma growth by regulating macrophage polarization via microRNA-26a/transforming growth factor beta 1/protein kinase B. Bioengineered 13:9548-9563 (2022). PubMed: 35387564
- Song YM et al. The Effects of Transforming Growth Factor-β1 on the Differentiation of Cell Organoids Composed of Gingiva-Derived Stem Cells. Biomed Res Int 2022:9818299 (2022). PubMed: 35872843